Article Text

Download PDFPDF
Aetiology-specific comparison of long-term outcome of deep anterior lamellar keratoplasty for corneal diseases
  1. Akiko Ogawa1,2,
  2. Takefumi Yamaguchi1,2,
  3. Hiroto Mitamura1,2,
  4. Daisuke Tomida1,
  5. Seika Shimazaki-Den1,
  6. Dogru Murat1,2,
  7. Yoshiyuki Satake1,
  8. Jun Shimazaki1,2
  1. 1Department of Ophthalmology, Ichikawa General Hospital, Tokyo Dental College, Chiba, Japan
  2. 2Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan
  1. Correspondence to Dr Takefumi Yamaguchi, Department of Ophthalmology, Ichikawa General Hospital, Tokyo Dental College, 5-11-13, Sugano, Ichikawa, Chiba 272-8513, Japan; tym.i.eye.i{at}


Aims To evaluate the long-term outcome of deep anterior lamellar keratoplasty (DALK) for the treatment of herpetic keratitis, keratoconus, stromal scars and corneal dystrophies.

Methods This retrospective consecutive case study includes 275 consecutive eyes of 254 patients who underwent DALK; 35 eyes with herpetic keratitis, 114 eyes with stromal scar, 93 eyes with keratoconus and 67 eyes with corneal dystrophy. Exclusion criteria included therapeutic DALK for the treatment of descemetocele or infectious keratitis, and eyes with limbal stem cell deficiency. Patients were examined at 1, 3 and 6 months, and 1, 3 and 5 years after DALK. Graft survival rate, best corrected visual acuity (BCVA), endothelial cell density (ECD) and postoperative complications were evaluated.

Results The mean postoperative follow-up duration was 51±41 months. The graft survival rate of all subjects was 96.8% at 1 year, 89.9% at 3 years, 83.5% at 5 years and 74.1% at 10 years. At 6 months, BCVA significantly improved from 1.14±0.54 to 0.22±0.21 in the keratoconus group, from 1.13±0.60 to 0.44±0.54 in the herpes group, from 1.00±0.59 to 0.49±0.38 in the stromal scar group and from 1.04±0.52 to 0.32±0.29 in the corneal dystrophy group (all, p<0.0001). BCVA stabilised after 6 months thereafter up to 5 years. ECD decreased just after DALK and maintained >1000 cell/mm2 at 5 years in all groups.

Conclusions DALK provides good visual acuity with slight ECD decrease over long term in all groups.

  • Cornea
  • Treatment Surgery

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • At a glance
    Keith Barton James Chodosh Jost Jonas